Table 2 Costs and utilities used in the reference case and sensitivity analyses.
Point estimate and 95% CI | |
---|---|
Total costs (FC) of AS if BASDAI ⩾4* | 4996 (3830 to 6737) |
Total costs (FC) of AS if BASDAI <4* | 2456 (1825 to 3275) |
Direct costs of AS if BASDAI ⩾4 | 4686 |
Direct costs of AS if BASDAI <4 | 1671 |
Total costs (HC) of AS if BASDAI ⩾4 | 15 950 |
Total costs (HC) of AS if BASDAI <4 | 10 453 |
Treatment costs for etanercept | 13 759 |
Treatment costs for infliximab first cycle (€/patient) | 7385 |
Treatment costs for infliximab | 21 335 |
Treatment costs for low dose infliximab first cycle (€/patient) | 3974 |
Treatment costs for low dose infliximab | 8612 |
Screening and prophylaxis TB (€) | 82 |
Treatment toxicity (€) | 2007 |
EQ‐5Dtime averaged if BASDAI ⩾4 | 0.59 (0.55 to 0.63) |
EQ‐5Dtime averaged if BASDAI <4 | 0.76 (0.74 to 0.79) |
EQ‐5D if BASDAI <4 and toxicity present | 0.5 (0 to 1.0)* utility BASDAI <4 |
Values are €/patient/year unless stated otherwise.
*CI based on the 95th centile method of bootstrapped costs.
AS, ankylosing spondylitis; BASDAI, Bath ankylosing spondylitis disease activity index; BASFI, Bath ankylosing spondylitis functional index; CI, confidence interval; EQ‐5D, EuroQol 5 dimensions; FC, friction costs method; HC, human capital approach; TB, tuberculosis.